Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease
- PMID: 12198618
- DOI: 10.1086/342601
Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease
Abstract
Despite standard therapy, cytomegalovirus (CMV) disease recurs in a significant proportion of organ transplant recipients. The kinetics of CMV load in response to therapy may allow early prediction of recurrence. CMV loads were obtained at regular intervals after starting ganciclovir therapy in 52 transplant recipients with CMV disease. Virus load kinetics were analyzed using decay curves to assess viral dynamics, including half-life and time to viral clearance. Recurrent CMV disease occurred in 12 (23%) of 50 patients. The time period to viral clearance was longer among patients with recurrence of CMV disease (P=.002), and lack of clearance was also associated among patients with disease recurrence (P<.001). Viral kinetics followed a logarithmic decay curve expressed by the equation y=y(0)e(-ax). Virus load half-life was 8.8 days among patients with recurrence versus 3.17 days among patients without recurrence (P=.001). This was not explainable by detectable ganciclovir resistance. CMV load kinetics are useful for identifying, at a very early stage, patients who are more likely to have recurrence.
Similar articles
-
Cytomegalovirus (CMV) glycoprotein B genotypes and response to antiviral therapy, in solid-organ-transplant recipients with CMV disease.J Infect Dis. 2003 Aug 15;188(4):581-4. doi: 10.1086/377002. Epub 2003 Jul 29. J Infect Dis. 2003. PMID: 12898447
-
Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation.J Infect Dis. 2000 Feb;181(2):717-20. doi: 10.1086/315242. J Infect Dis. 2000. PMID: 10669361
-
[Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].Enferm Infecc Microbiol Clin. 2010 Jan;28(1):6-12. doi: 10.1016/j.eimc.2009.01.010. Epub 2009 May 1. Enferm Infecc Microbiol Clin. 2010. PMID: 19409666 Clinical Trial. Spanish.
-
Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients.Semin Respir Infect. 2002 Dec;17(4):265-73. doi: 10.1053/srin.2002.36447. Semin Respir Infect. 2002. PMID: 12497543 Review.
-
Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.Transplantation. 2006 Jan 27;81(2):139-45. doi: 10.1097/01.tp.0000183970.71366.da. Transplantation. 2006. PMID: 16436954 Review.
Cited by
-
Differential decay kinetics of human cytomegalovirus glycoprotein B genotypes following antiviral chemotherapy.J Clin Virol. 2012 May;54(1):56-60. doi: 10.1016/j.jcv.2012.01.015. Epub 2012 Mar 10. J Clin Virol. 2012. PMID: 22410132 Free PMC article.
-
Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens.Antimicrob Agents Chemother. 2014;58(1):128-35. doi: 10.1128/AAC.00561-13. Epub 2013 Oct 21. Antimicrob Agents Chemother. 2014. PMID: 24145525 Free PMC article.
-
Therapeutic Drug Monitoring and Biomarkers; towards Better Dosing of Antimicrobial Therapy.Pharmaceutics. 2024 May 17;16(5):677. doi: 10.3390/pharmaceutics16050677. Pharmaceutics. 2024. PMID: 38794338 Free PMC article.
-
New developments in the management of cytomegalovirus infection after solid organ transplantation.Drugs. 2010 May 28;70(8):965-81. doi: 10.2165/10898540-000000000-00000. Drugs. 2010. PMID: 20481654 Review.
-
Interpreting quantitative cytomegalovirus DNA testing: understanding the laboratory perspective.Clin Infect Dis. 2012 Jun;54(12):1793-7. doi: 10.1093/cid/cis212. Epub 2012 Mar 12. Clin Infect Dis. 2012. PMID: 22412060 Free PMC article.